Drug Discovery Tag

Cephalotane-type C20 diterpenoids from Cephalotaxus fortunei var. alpina

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text] Seventeen new cephalotane-type diterpenoids, fortalides A-Q (1-17), along with five known analogues, were isolated from the seeds of Cephalotaxus fortunei var. alpina. Their structures were determined by extensive spectroscopic methods, as well as electronic circular dichroism (ECD) and X-ray crystallographic...

Read More
T. cruzi amastigtoes in skeletal muscle cell

Researchers discover potential treatment for Chagas disease

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text] [caption id="attachment_7450" align="aligncenter" width="600"] The skeletal muscle of a mouse infected with Trypanosoma cruzi is shown under a microscope. (Submitted by Fernando Sanchez)[/caption] The condition affects tens of millions across the Americas but lacks effective treatments Researchers from the...

Read More
University of Georgia Distinguished Research Professor, Department of Cellular Biology, and UGA Athletic Association Distinguished Professor in Biological Sciences

In the News: New study from the Tarleton Research Group

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text]Rick Tarleton and colleagues recently published their new study, "Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates" in Nature Microbiology. Check out these news stories about the study. Behind...

Read More
Steve Maher

Researchers implement new tool to screen drugs for treating malaria relapses

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text] [caption id="attachment_6971" align="aligncenter" width="600"] Steve Maher, assistant research scientist in the Center for Tropical Emerging and Global Diseases, leads a team of researchers who have implemented a new screening tool to determine if a drug candidate kills...

Read More

Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text]Improved control of Plasmodium vivax malaria can be achieved with the discovery of new antimalarials with radical cure efficacy, including prevention of relapse caused by hypnozoites residing in the liver of patients. We screened several compound libraries...

Read More
Chet Joyner and Dennis Kyle

UGA researchers developing new models for malaria drug development and testing

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text] [caption id="attachment_6923" align="aligncenter" width="600"] CTEGD member Chet Joyner and CTEGD director Dennis Kyle receive a grant from the Bill & Melinda Gates Foundation for malaria drug development and testing[/caption] Two UGA researchers are working to make it easier...

Read More
Belen Cassera

Researchers to test drug candidates to treat malaria

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text]by Donna Huber [caption id="attachment_6909" align="aligncenter" width="600"] Belen Cassera is leading a research team that will test two new drugs for the treatment of malaria. The team's work will be funded by a $3.7 million grant from the...

Read More

Synthesis of Mono- and Bisperoxide-Bridged Artemisinin Dimers to Elucidate the Contribution of Dimerization to Antimalarial Activity

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text] During the past decade, artemisinin as an antimalarial has been in the spotlight, in part due to the Nobel Prize in Physiology or Medicine awarded to Tu Youyou. While many studies have been completed detailing the significant...

Read More

Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text]Diseases caused by pathogenic free-living amoebae include primary amoebic meningoencephalitis (Naegleria fowleri), granulomatous amoebic encephalitis (Acanthamoeba spp.), Acanthamoeba keratitis, and Balamuthia amoebic encephalitis (Balamuthia mandrillaris). Each of these are difficult to treat and have high morbidity and...

Read More